26
|
Horton E, Montgomery R, Wilkinson M. Allergic contact dermatitis caused by copper in a malachite necklace. Contact Dermatitis 2018; 77:120-121. [PMID: 28703344 DOI: 10.1111/cod.12791] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/21/2016] [Revised: 02/09/2017] [Accepted: 02/10/2017] [Indexed: 11/28/2022]
|
27
|
Montgomery R, Boswell T, Mahida N. Pseudomonas aeruginosa control in healthcare settings: outpatient dialysis units are not augmented care units. J Hosp Infect 2018; 98:65-66. [DOI: 10.1016/j.jhin.2017.09.027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2017] [Accepted: 09/27/2017] [Indexed: 10/18/2022]
|
28
|
Montgomery R, Wilkinson M. Allergic contact urticaria secondary to hair dye use. Contact Dermatitis 2017; 77:257-259. [DOI: 10.1111/cod.12811] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2017] [Revised: 03/06/2017] [Accepted: 03/09/2017] [Indexed: 12/01/2022]
|
29
|
Montgomery R. AGE-RELATED CHANGES IN INNATE IMMUNE CELL FUNCTION. Innov Aging 2017. [DOI: 10.1093/geroni/igx004.4559] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
30
|
Hassell K, Ngongo W, Montgomery R, Hornick L. (374) Ketamine infusion as an analgesic adjunct in the management of severe pain in patients with sickle cell disease. THE JOURNAL OF PAIN 2017. [DOI: 10.1016/j.jpain.2017.02.348] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
31
|
Attard G, Montgomery R, Vaishampayan U, Gordon M, Smith D, Antonarakis E, Rudsinski E, Perabo F, Chi K, Fizazi K. A phase 1/2 open-label study of safety and antitumor activity of EPI-506, a novel AR N-terminal domain inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC) with progression after enzalutamide or abiraterone. ACTA ACUST UNITED AC 2016. [DOI: 10.1016/s1569-9056(16)30439-0] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
32
|
Nguyen B, Montgomery R, Fadia M, Wang J, Ali S. 58P PDL1 expression associated with worse survival outcome in malignant pleural mesothelioma. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw574.031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
33
|
Khunda A, Al-Maiyah M, Eardley WGP, Montgomery R. The management of tibial fracture non-union using the Taylor Spatial Frame. J Orthop 2016; 13:360-3. [PMID: 27453643 DOI: 10.1016/j.jor.2016.07.002] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/30/2016] [Accepted: 07/01/2016] [Indexed: 11/19/2022] Open
Abstract
We reviewed 40 complex tibial non-unions treated with Taylor Spatial Frames. 39 healed successfully. Using the ASAMI scoring, we obtained 33 excellent, 5 good, 1 fair and 1 poor bone results. The functional results were excellent in 29 patients, good in 8, fair in two and poor in one. Mean patient satisfaction score was 95%. All but one patient would have the same treatment again. 28 of the 36 patients in work when injured, returned to work at the time of their final review. Four patients had an adverse event requiring significant intervention. Average treatment cost was approximately £26,000/patient.
Collapse
|
34
|
Montgomery R, Stocks SJ, Wilkinson SM. Contact allergy resulting from the use of acrylate nails is increasing in both users and those who are occupationally exposed. Contact Dermatitis 2016; 74:120-2. [DOI: 10.1111/cod.12497] [Citation(s) in RCA: 47] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2015] [Revised: 09/21/2015] [Accepted: 09/22/2015] [Indexed: 11/30/2022]
|
35
|
McAdams-DeMarco MA, Ying H, Olorundare I, King EA, Desai N, Dagher N, Lonze B, Montgomery R, Walston J, Segev DL. Frailty and Health-Related Quality of Life in End Stage Renal Disease Patients of All Ages. J Frailty Aging 2016; 5:174-179. [PMID: 29240319 PMCID: PMC6205225] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
BACKGROUND: Frailty is associated with worse health-related quality of life (HRQOL) in older adults and worse clinical outcomes in adults of all ages with end stage renal disease (ESRD). It is unclear whether frail adults of all ages with ESRD are more likely to experience worse HRQOL. OBJECTIVE: The goal of this study was to identify factors associated with worsening HRQOL in this population. DESIGN, SETTING AND MEASUREMENTS: We studied 233 adults of all ages with ESRD enrolled (11/2009-11/2013) in a longitudinal cohort study. Frailty status was measured at enrollment and HRQOL was reported (Excellent, Very Good, Good, Fair or Poor) at the initial assessment and follow-up (median follow-up 9.4 months). We studied factors associated with Fair/Poor HRQOL at follow-up using logistic regression and factors associated with HRQOL change using multinomial regression. All models were adjusted for age, sex, race, education, BMI, diabetes status, history of a previous transplant, type of dialysis and time between assessments. RESULTS: Fair/Poor HRQOL was reported by 28% at initial assessment and 33% at follow-up. 47.2% of participants had stable HRQOL, 22.8% better HRQOL, and 30.0% worse HRQOL at follow-up (P<0.001). In adjusted models, only frailty was associated with Fair/Poor HRQOL at follow-up (OR: 2.79, 95% CI: 1.32-5.90) and worsening HRQOL at follow-up (RR: 2.91, 95%CI: 1.08-7.80). CONCLUSIONS: Frail adults of all ages with ESRD are more likely to experience fair/poor HRQOL and worsening HRQOL over time. Frailty represents a state of decreased physiologic reserve that impacts not only clinical outcomes but also the patient-centered outcome of HRQOL.
Collapse
|
36
|
Bodó I, Eikenboom J, Montgomery R, Patzke J, Schneppenheim R, Di Paola J. Platelet-dependent von Willebrand factor activity. Nomenclature and methodology: communication from the SSC of the ISTH. J Thromb Haemost 2015; 13:1345-50. [PMID: 25858564 PMCID: PMC5576173 DOI: 10.1111/jth.12964] [Citation(s) in RCA: 99] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2015] [Accepted: 03/29/2015] [Indexed: 12/26/2022]
|
37
|
Seder E, Biselli A, Pisano S, Niccolai S, Smith GD, Joo K, Adhikari K, Amaryan MJ, Anderson MD, Anefalos Pereira S, Avakian H, Battaglieri M, Bedlinskiy I, Bono J, Boiarinov S, Bosted P, Briscoe W, Brock J, Brooks WK, Bültmann S, Burkert VD, Carman DS, Carlin C, Celentano A, Chandavar S, Charles G, Colaneri L, Cole PL, Contalbrigo M, Crabb D, Crede V, D'Angelo A, Dashyan N, De Vita R, De Sanctis E, Deur A, Djalali C, Doughty D, Dupre R, El Fassi L, Elouadrhiri L, Eugenio P, Fedotov G, Fegan S, Filippi A, Fleming JA, Fradi A, Garillon B, Garçon M, Gevorgyan N, Ghandilyan Y, Giovanetti KL, Girod FX, Goetz JT, Gohn W, Gothe RW, Griffioen KA, Guegan B, Guidal M, Guo L, Hafidi K, Hakobyan H, Hanretty C, Harrison N, Hattawy M, Hirlinger Saylor N, Holtrop M, Hughes SM, Ilieva Y, Ireland DG, Ishkhanov BS, Isupov EL, Jo HS, Joosten S, Keith CD, Keller D, Khachatryan G, Khandaker M, Kim A, Kim W, Klein A, Klein FJ, Koirala S, Kubarovsky V, Kuhn SE, Lenisa P, Livingston K, Lu HY, MacGregor IJD, Markov N, Mayer M, McKinnon B, Meekins DG, Mineeva T, Mirazita M, Mokeev V, Montgomery R, Moody CI, Moutarde H, Movsisyan A, Munoz Camacho C, Nadel-Turonski P, Niculescu I, Osipenko M, Ostrovidov AI, Paolone M, Pappalardo LL, Park K, Park S, Pasyuk E, Peng P, Phelps W, Pogorelko O, Price JW, Prok Y, Protopopescu D, Puckett AJR, Ripani M, Rizzo A, Rosner G, Rossi P, Roy P, Sabatié F, Salgado C, Schott D, Schumacher RA, Senderovich I, Simonyan A, Skorodumina I, Sokhan D, Sparveris N, Stepanyan S, Stoler P, Strakovsky II, Strauch S, Sytnik V, Taiuti M, Tang W, Tian Y, Ungaro M, Voskanyan H, Voutier E, Walford NK, Watts DP, Wei X, Weinstein LB, Wood MH, Zachariou N, Zana L, Zhang J, Zonta I. Longitudinal target-spin asymmetries for deeply virtual compton scattering. PHYSICAL REVIEW LETTERS 2015; 114:032001. [PMID: 25658994 DOI: 10.1103/physrevlett.114.032001] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/24/2014] [Indexed: 06/04/2023]
Abstract
A measurement of the electroproduction of photons off protons in the deeply inelastic regime was performed at Jefferson Lab using a nearly 6 GeV electron beam, a longitudinally polarized proton target, and the CEBAF Large Acceptance Spectrometer. Target-spin asymmetries for ep→e^{'}p^{'}γ events, which arise from the interference of the deeply virtual Compton scattering and the Bethe-Heitler processes, were extracted over the widest kinematics in Q^{2}, x_{B}, t, and ϕ, for 166 four-dimensional bins. In the framework of generalized parton distributions, at leading twist the t dependence of these asymmetries provides insight into the spatial distribution of the axial charge of the proton, which appears to be concentrated in its center. These results also bring important and necessary constraints for the existing parametrizations of chiral-even generalized parton distributions.
Collapse
|
38
|
Urwin R, Montgomery R, Hussain W. The 'inverted' advancement and inferior rotation of the nasal sidewall (AIRNS) flap for defects of the medial canthus. Br J Dermatol 2014; 170:751-3. [PMID: 24641693 DOI: 10.1111/bjd.12693] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
39
|
Warburton KL, McPhee MJ, Savage LJ, Honan AE, Montgomery R, Ghazavi M, Torley D, Shams K, Ingram JR. Management of morphoea: results of a national survey of U.K. clinicians. Br J Dermatol 2014; 171:1243-5. [PMID: 24749777 DOI: 10.1111/bjd.13062] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
40
|
Cipiccia S, Wiggins SM, Maneuski D, Brunetti E, Vieux G, Yang X, Issac RC, Welsh GH, Anania M, Islam MR, Ersfeld B, Montgomery R, Smith G, Hoek M, Hamilton DJ, Lemos NRC, Symes DR, Rajeev PP, Shea VO, Dias JM, Jaroszynski DA. Compton scattering for spectroscopic detection of ultra-fast, high flux, broad energy range X-rays. THE REVIEW OF SCIENTIFIC INSTRUMENTS 2013; 84:113302. [PMID: 24289391 DOI: 10.1063/1.4825374] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/02/2023]
Abstract
Compton side-scattering has been used to simultaneously downshift the energy of keV to MeV energy range photons while attenuating their flux to enable single-shot, spectrally resolved, measurements of high flux X-ray sources to be undertaken. To demonstrate the technique a 1 mm thick pixelated cadmium telluride detector has been used to measure spectra of Compton side-scattered radiation from a Cobalt-60 laboratory source and a high flux, high peak brilliance X-ray source of betatron radiation from a laser-plasma wakefield accelerator.
Collapse
|
41
|
Berntorp E, Fuchs B, Makris M, Montgomery R, Flood V, O'Donnell JS, Federici AB, Lillicrap D, James P, Budde U, Morfini M, Petrini P, Austin S, Kannicht C, Jiménez-Yuste V, Lee C. Third Åland islands conference on von Willebrand disease, 26-28 September 2012: meeting report. Haemophilia 2013; 19 Suppl 3:1-18. [PMID: 23383607 DOI: 10.1111/hae.12078] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/28/2012] [Indexed: 01/03/2023]
Abstract
The first meeting of international specialists in the field of von Willebrand disease (VWD) was held in the Åland islands in 1998 where Erik von Willebrand had first observed a bleeding disorder in some members of a family from Föglö and a summary of the meeting was published in 1999. The second meeting was held in 2010 and a report of the meeting was published in 2012. Topics covered included progress in understanding of VWD over the last 50 years; multimers; classification of VWD; pharmacokinetics and laboratory assays; genetics; treating the paediatric patient; prophylaxis; geriatrics; gene therapy and treatment guidelines. This third meeting held over 3 days covered the structure and function of von Willebrand factor (VWF); type 1 VWD, the most common form of the disease; a lifespan of pharmacokinetics in VWD; detecting inhibitors in VWD patients; and special challenges in understanding and treating the female VWD patient.
Collapse
|
42
|
Berntorp E, Peake I, Budde U, Laffan M, Montgomery R, Windyga J, Goodeve A, Petrini P, von Depka M, Miesbach W, Lillicrap D, Federici AB, Lassila R, White G. von Willebrand's disease: a report from a meeting in the Åland islands. Haemophilia 2012; 18 Suppl 6:1-13. [PMID: 22906074 DOI: 10.1111/j.1365-2516.2012.02925.x] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
von Willebrand's disease (VWD) is probably the most common bleeding disorder, with some studies indicating that up to 1% of the population may have the condition. Over recent years interest in VWD has fallen compared to that of haemophilia, partly the result of focus on blood-borne diseases such as HIV and hepatitis. Now the time has come to revisit VWD, and in view of this some 60 international physicians with clinical and scientific interest in VWD met over 4 days in 2010 in the Åland islands to discuss state-of-the-art issues in the disease. The Åland islands are where Erik von Willebrand had first observed a bleeding disorder in a number of members of a family from Föglö, and 2010 was also the 140th anniversary of his birth. This report summarizes the main papers presented at the symposium; topics ranged from genetics and biochemistry through to classification of VWD, pharmacokinetics and laboratory assays used in the diagnosis of the disease, inhibitors, treatment guidelines in different age groups including the elderly who often have comorbid conditions that present challenges, and prophylaxis. Other topics included managing surgeries in patients with VWD and the role of FVIII in VWF replacement, a controversial subject.
Collapse
|
43
|
Sharif A, Lonze B, Hillier J, Zachary A, Leffell M, Alachkar N, Kraus E, Dagher N, Desai N, Segev D, Montgomery R. Outcomes from Combining Kidney Paired Donation and Desensitization: An Approach to Kidney Transplantation for the Most Highly Sensitized Patients. Transplantation 2012. [DOI: 10.1097/00007890-201211271-00151] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
44
|
Montgomery R, Mullins CD, Abernethy AP, Hussain A, Tunis SR. Recommendations for designing comparative effectiveness studies in oncology. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e16550] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
45
|
Seibert F, Chen E, Perry M, Briggs S, Montgomery R, Rochelle G. UT/SRP CO2 capture pilot plant — Operating experience and procedures. ACTA ACUST UNITED AC 2011. [DOI: 10.1016/j.egypro.2011.02.032] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
46
|
Massingham WE, Montgomery R, Smith F, Thomas BRJ. Organic fluorides. XII. A simple rotating reactor for fluorination. ACTA ACUST UNITED AC 2007. [DOI: 10.1002/jctb.5010020414] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
47
|
Mehta TK, Hoque MO, Ugarte R, Rahman MH, Kraus E, Montgomery R, Melancon K, Sidransky D, Rabb H. Quantitative detection of promoter hypermethylation as a biomarker of acute kidney injury during transplantation. Transplant Proc 2007; 38:3420-6. [PMID: 17175292 PMCID: PMC2048491 DOI: 10.1016/j.transproceed.2006.10.149] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2006] [Indexed: 12/31/2022]
Abstract
Aberrant promoter hypermethylation, also known as epigenetics, is thought to be a promising biomarker approach to diagnose malignancies. Kidney repair after injury is a recapitulation of normal morphogenesis, with similarities to malignant transformation. We hypothesized that changes in urine epigenetics could be a biomarker approach during early kidney transplant injury and repair. We examined urine DNA for aberrant methylation of two gene promoters (DAPK and CALCA) by quantitative methylation-specific polymerase chain reaction from 13 deceased and 10 living donor kidney transplant recipients on postoperative day 2 and 65 healthy controls. Results were compared with clinical outcomes and to results of the kidney biopsy. Transplant recipients were significantly more likely to have aberrant hypermethylation of the CALCA gene promoter in urine than healthy controls (100% vs 31%; P < .0001). There was increased CALCA hypermethylation in the urine of deceased versus living donor transplants (21.60 +/- 12.5 vs 12.19 +/- 4.7; P = .04). Furthermore, there was a trend toward increased aberrant hypermethylation of urine CALCA in patients with biopsy-proven acute tubular necrosis versus acute rejection and slow or prompt graft function (mean: 20.40 +/- 6.9, 13.87 +/- 6.49, 17.17 +/- 13.4; P = .67). However, there was no difference of CALCA hypermethylation in urine of patients with delayed graft function versus those with slow or prompt graft function (16.9 +/- 6.2 vs 18.5 +/- 13.7, respectively; P = .5). There was no aberrant hypermethylation of DAPK in the urine of transplant patients. Urine epigenetics is a promising biomarker approach for acute ischemic injury in transplantation that merits future study.
Collapse
|
48
|
Patil S, Montgomery R. Management of complex tibial and femoral nonunion using the Ilizarov technique, and its cost implications. ACTA ACUST UNITED AC 2006; 88:928-32. [PMID: 16798998 DOI: 10.1302/0301-620x.88b7.17639] [Citation(s) in RCA: 80] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
We reviewed 78 femoral and tibial nonunions treated between January 1992 and December 2003. Of these, we classified 41 in 40 patients as complex cases because of infection (22), bone loss (6) or failed previous surgery (13). The complex cases were all treated with Ilizarov frames. At a mean time of 14.1 months (4 to 38), 39 had healed successfully. Using the Association for the Study and Application of the Methods of Ilizarov scoring system we obtained 17 excellent, 14 good, four fair and six poor bone results. The functional results were excellent in 14 patients, good in 14, fair in two and poor in two. A total of six patients were lost to follow-up and two had amputations so were not evaluated for final functional assessment. All but two patients were very satisfied with the results. The average cost of treatment to the treating hospital was approximately £30 000 per patient. We suggest that early referral to a tertiary centre could reduce the morbidity and prolonged time off work for these patients. The results justify the expense, but the National Health Service needs to make financial provision for the reconstruction of this type of complex nonunion.
Collapse
|
49
|
Candelaria D, Armijo B, Montgomery R, Lee F, Moll S, Garcia D, Liebmann J, Libby E. Thalidomide increases thrombin generation in multiple myeloma patients. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.7602] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
7602 Background: Numerous reports have demonstrated that the clinical use of thalidomide (THAL) carries a risk for deep venous thrombosis. Only limited investigations into the causative mechanisms for this complication have been conducted. Thrombin generation is a global measurement of hyper or hypocoagulability that has not been used to examine the hypercoagulable state caused by THAL. The aim of this study was to determine if THAL affects thrombin generation in patients with multiple myeloma (MM). Methods: MM patients on and off THAL were recruited. Patients were considered to be “on THAL” if they had been taking the medication for at least three months and “off THAL” if they had not been taking the medication for at least three months. Coagulation tubes of blood containing 3.2% sodium citrate were drawn from each patient. Platelet poor plasma was prepared from these specimens using standard technique. The samples were snap frozen at -70 C and stored until analysis. Thrombin generation was measured using the Calibrated Automated Thrombogram as described by Hemker(Pathophysiol Haemo Thromb 2003;33:4–15) using a microplate fluorometer, the Fluoroskan Ascent from Thermo Electron and the Thrombinoscope software package. The endogenous thrombin potential or ETP (area under the thrombin generation curve) and peak thrombin generation (the maximum release of thrombin per unit of time) were the variables of interest for this study. Results: Twenty seven patients were recruited. Five were excluded from analysis because they were on warfarin or enoxaparin. The normal ETP in females is 1803 ± 241 nM*min and in males is 1745 ± 259 nM *min. Normal peak thrombin generation in females is 318.5 ± 52.9 nM and in males is 293.4 ± 48.5 nM. The t-test was used to compare subjects to normal values.Peak thrombin generation was significantly increased in the 9 subjects taking THAL, 374 ± 10.6 nM (p<0.001) and in the 13 subjects not taking THAL, 352 ± 14.7 nM (p=0.009) when compared to normal values. The ETP was not significantly increased 1818 ± 10.7 nM*min (p=0.69) in subjects not taking THAL. However, ETP was increased in subjects taking THAL, 1939± 90 nM*min and showed a trend toward statistical significance (p=0.10). Conclusions: Thalidomide therapy increases thrombin generation significantly in patients with MM. [Table: see text]
Collapse
|
50
|
Rivkin SE, Markman M, Petersen J, Montgomery R. Influence of tumor type, disease status, and patient age on self-reported interest regarding participation in cancer clinical trials. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.6100] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
6100 Background: There is limited data available regarding the reasons cancer patients decide to enter clinical trials. Methods: To explore this issue, aggregate responses to the question, “Are you interested in learning about clinical trials for your condition?” obtained from > 115,000 cancer patients (or their families) who entered data into one of several proprietary decision-support programs embedded within approximately 100 cancer-related Internet sites, were analyzed. Results: The proportion of patients (or their families) who expressed interest in learning of the availability of clinical trials ranged from as low as 21% (endometrial and cervix cancer patients > 80 years old; n=178) to as high as 85% (recurrent ovarian cancer patients, aged 51–60; n=842). Patients > 80 years old, regardless of sex, tumor type, or disease status, were substantially less likely to desire such information. Patients with self-declared more “serious conditions” (e.g., metastatic breast cancer [71%; n=5,444], recurrent prostate cancer [70%; n=4,121]), and those with cancers widely known to have a poor prognosis (e.g., non-small cell lung cancer [75%; n=23,298]), were more likely to request data on trials, than those with an overall more “favorable” prognosis (e.g., newly diagnosed prostate cancer [46%; n=21,348]). There were no observed differences in interest between men and women with similar conditions. Conclusion: In this large data base, major differences in self-expressed interest regarding availability of clinical trails were observed. Particularly notable were the reduced interest among the very elderly, and the increased interest by patients with the most serious cancer-related conditions. [Table: see text]
Collapse
|